Literature DB >> 18190889

Hughes Syndrome (the antiphospholipid syndrome): ten clinical lessons.

Graham R V Hughes1.   

Abstract

The APS was described 25 years ago as a triad of manifestations (GRV Hughes). During the last 3 decades the disease became more systemic than systemic lupus erythematosus (SLE). The paper entails many of the old clinical findings as well as novel ones which are still not well documented in large series. The authors also refer to the second hit theory of infectious origin of APS. How to treat and indications for self monitoring the INR are detailed. The question of whether specific IVIG (directed against anti cardiolipin) or anti CD 20 be incorporated into the therapeutic armamentarium employed in APS will be answered in the near future.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18190889     DOI: 10.1016/j.autrev.2007.11.017

Source DB:  PubMed          Journal:  Autoimmun Rev        ISSN: 1568-9972            Impact factor:   9.754


  12 in total

Review 1.  Reversible cerebral vasoconstriction syndrome (RCVS) in antiphospholipid antibody syndrome (APLA): the role of centrally acting vasodilators. Case series and review of literature.

Authors:  Sarthak Gupta; Robert Zivadinov; Deepa Ramasamy; Julian L Ambrus
Journal:  Clin Rheumatol       Date:  2013-11-26       Impact factor: 2.980

2.  A rarely seen syndrome in rehabilitation of hemiplegia: antiphospholipid antibody-negative Sneddon's syndrome.

Authors:  Ayla Akbal; Aydan Kurtaran; Barin Selçuk; Murat Ersöz; Müfit Akyüz
Journal:  Rheumatol Int       Date:  2009-08-21       Impact factor: 2.631

3.  Leg ulcers in the antiphospholipid syndrome may be considered as a form of pyoderma gangrenosum and they respond favorably to treatment with immunosuppression and anticoagulation.

Authors:  Carlos A Cañas; Carlos E Durán; Juan C Bravo; Dora E Castaño; Gabriel J Tobón
Journal:  Rheumatol Int       Date:  2010-03-28       Impact factor: 2.631

4.  Cavernous sinus thrombosis in a patient with nephrotic syndrome.

Authors:  David Navarro; Ana Carina Ferreira; Helena Viana; Fernanda Carvalho; Fernando Nolasco
Journal:  CEN Case Rep       Date:  2017-05-17

Review 5.  Cutting-edge issues in coronary disease and the primary antiphospholipid syndrome.

Authors:  Roberta Gualtierotti; Martina Biggioggero; Pier Luigi Meroni
Journal:  Clin Rev Allergy Immunol       Date:  2013-02       Impact factor: 8.667

6.  Patients' experiences of a diagnosis of Hughes' syndrome.

Authors:  P T Donnan; M J McDonald
Journal:  Clin Rheumatol       Date:  2009-05-21       Impact factor: 2.980

Review 7.  Autoimmunity and recurrent pregnancy losses.

Authors:  Ricard Cervera; Juan Balasch
Journal:  Clin Rev Allergy Immunol       Date:  2010-12       Impact factor: 8.667

Review 8.  Antiphospholipid syndrome (APS) revisited: Would migraine headaches be included in future classification criteria?

Authors:  Mohammad Hassan A Noureldine; Ali A Haydar; Ahmad Berjawi; Rody Elnawar; Ahmad Sweid; Munther A Khamashta; Graham R V Hughes; Imad Uthman
Journal:  Immunol Res       Date:  2017-02       Impact factor: 2.829

9.  The pathogenesis of neural injury in animal models of the antiphospholipid syndrome.

Authors:  Aviva Katzav; Yehuda Shoenfeld; Joab Chapman
Journal:  Clin Rev Allergy Immunol       Date:  2010-04       Impact factor: 8.667

10.  Vascular disease in systemic lupus erythematosus.

Authors:  Athina Pyrpasopoulou; Sofia Chatzimichailidou; Spyros Aslanidis
Journal:  Autoimmune Dis       Date:  2012-08-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.